Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

In­vestors are sell­ing off shares of Ful­crum Ther­a­peu­tics $FULC af­ter their lead drug failed in a Phase II tri­al.

The com­pa­ny, found­ed three years ago on new re­search tech­niques such as CRISPR screen­ing, iso­lat­ed a gene called DUX4 they be­lieved to have a cen­tral role in fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy, where pa­tients’ mus­cle dies and is re­placed by fat. And to tar­get it, they li­censed a Glax­o­SmithK­line drug that had failed as a car­dio drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER